Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules

被引:68
作者
Tamada, K [1 ]
Chen, LP [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Dept Dermatol & Oncol, Baltimore, MD 21287 USA
关键词
D O I
10.1007/s00262-005-0081-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.
引用
收藏
页码:355 / 362
页数:8
相关论文
共 92 条
[1]   CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection [J].
Afford, SC ;
Randhawa, S ;
Eliopoulos, AG ;
Hubscher, SG ;
Young, LS ;
Adams, DH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) :441-446
[2]  
ASHER A, 1987, J IMMUNOL, V138, P963
[3]  
Browning JL, 1997, J IMMUNOL, V159, P3288
[4]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[5]   Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival [J].
Cho, HR ;
Kwon, B ;
Yagita, H ;
La, S ;
Lee, EA ;
Kim, JE ;
Akiba, H ;
Kim, J ;
Suh, JH ;
Vinay, DS ;
Ju, SA ;
Kim, BS ;
Mittler, RS ;
Okumura, K ;
Kwon, BS .
TRANSPLANT INTERNATIONAL, 2004, 17 (07) :351-361
[6]   4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells [J].
Choi, BK ;
Bae, JS ;
Choi, EM ;
Kang, WJ ;
Sakaguchi, S ;
Vinay, DS ;
Kwon, BS .
JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 75 (05) :785-791
[7]  
Couderc B, 1998, CANCER GENE THER, V5, P163
[8]  
CREAGAN ET, 1988, CANCER, V62, P2467, DOI 10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO
[9]  
2-5
[10]  
CREAVEN PJ, 1987, CANCER CHEMOTH PHARM, V20, P137